Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter bought 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was bought at an average price of $4.77 per share, with a total value of $238,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Vital Therapies, Inc. (NASDAQ VTL) opened at $5.60 on Thursday. Vital Therapies, Inc. has a 1-year low of $2.25 and a 1-year high of $6.50.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings data on Wednesday, October 25th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. During the same period in the previous year, the company posted ($0.32) earnings per share. sell-side analysts forecast that Vital Therapies, Inc. will post -1.26 EPS for the current fiscal year.

Several research firms recently issued reports on VTL. Raymond James Financial reissued a “buy” rating on shares of Vital Therapies in a research note on Tuesday, December 5th. BidaskClub downgraded Vital Therapies from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Zacks Investment Research downgraded Vital Therapies from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Finally, ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a report on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its stake in Vital Therapies by 0.9% during the 3rd quarter. Victory Capital Management Inc. now owns 2,603,089 shares of the company’s stock worth $13,145,000 after buying an additional 23,810 shares during the last quarter. Granahan Investment Management Inc. MA grew its stake in Vital Therapies by 51.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 388,282 shares of the company’s stock worth $1,961,000 after buying an additional 131,828 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after buying an additional 168,705 shares during the last quarter. LMR Partners LLP purchased a new position in Vital Therapies during the 2nd quarter worth approximately $396,000. Finally, Blair William & Co. IL grew its stake in Vital Therapies by 67.2% during the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after buying an additional 40,000 shares during the last quarter. Institutional investors and hedge funds own 24.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Vital Therapies, Inc. (VTL) Director Acquires $238,500.00 in Stock” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/14/vital-therapies-inc-vtl-director-acquires-238500-00-in-stock.html.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.